GLPwatch
Papers (10410)
Page 148 of 174, ranked by citation count.
- Pharmacist-led management of GLP-1 and GIP/GLP-1 receptor agonists in type 2 diabetes mellitus.
- Early glucagon-like peptide-1 receptor agonist use after myocardial infarction in patients with type 2 diabetes.
- Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study.
- JNK3 regulates β cell responses to incretins in human islets and mouse models.
- [The GLP-1 analogue battle: effects of semaglutide 0,5 mg/weekly versus liraglutide 3 mg/daily on anthropometric parameters after 3 months in a real world-scenario].
- Effects of semaglutide on obstructive sleep apnea risk and outcomes in patients with obesity.
- Comparison of IBD-related outcomes in patients with obesity treated with GLP-1 receptor agonists versus bariatric surgery.
- The LEADER trial in type 2 diabetes: Were the characteristics and outcomes of the participants representative?
- Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape.
- Is semaglutide cost-effective at closing the gap for Aboriginal and Torres Strait Islander Australians with cardiovascular disease and obesity without type 2 diabetes?
- Liraglutide Ameliorates Injury-Related Vascular Repair by Activating Autophagy Through Modulation of the PI3K-mTOR Signaling Pathway.
- Fixing the food environment: beyond weight-loss drugs.
- [The effects of compound CX09040 on the inhibition of PTP1B and protection of pancreatic β cells].
- Treatment of persistent or recurrent type 2 diabetes after metabolic surgery.
- Evaluation of unmet medical need among Japanese patients with type 2 diabetes mellitus and efficacy of Lixisenatide treatment among Asian type 2 diabetes mellitus patients.
- IDegLira: combining efficacy, durability, and convenience?
- Comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials".
- Tirzepatide associated autoimmune encephalitis: A case report.
- Dulaglutide rescues the elevated testicular dysfunction in a mouse model of high-fat diet-induced obesity.
- Modeling the Effect of Subcutaneous Lixisenatide on Glucoregulatory Endocrine Secretions and Gastric Emptying in Type 2 Diabetes to Simulate the Effect of iGlarLixi Administration Timing on Blood Sugar Profiles.
- Incretin Analogs for Weight Management in Adults Without Diabetes.
- Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis.
- CCK Response Deficiency in Synphilin-1 Transgenic Mice.
- Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type 2 diabetes: A retrospective, observational post-marketing study.
- Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes.
- Population pharmacokinetics of lyophilized recombinant glucagon-like peptide-1 receptor agonist (recombinant exendin-4, rE-4) in Chinese patients with type 2 diabetes mellitus .
- [Glucagon-like peptide-1 analogues: effects on body weight and glycemia].
- The impact of extended release exenatide as adjuvant therapy on hemoglobin A1C, weight, and total daily dose of insulin in patients with type 2 diabetes mellitus using U-500 insulin.
- Positron emission tomography to assess drug occupancy at peripheral and central incretin receptors.
- Metformin-Enhanced Digital Therapeutics for the Affordable Primary Prevention of Diabetes and Cardiovascular Diseases: Advancing Low-Cost Solutions for Lifestyle-Related Chronic Disorders.
- M14 substitutions in exanatide modulate alpha-synuclein aggregation.
- Glucagon-like peptide-1 receptor agonists in patients with heart failure with reduced ejection fraction.
- Weight and body composition outcomes with liraglutide in individuals with well-treated hypothyroidism: A retrospective case-control study.
- Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients.
- Top studies of 2023 relevant to primary care: From the PEER team.
- Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin.
- A Bivalent Protease-Activated Receptor-Derived Peptide Mimics Neuronal Anti-Apoptotic Activity of Activated Protein C.
- Improvement in Helicobacter pylori Eradication Among Adults Receiving Semaglutide: A Population-Based Propensity-Score-Adjusted Analysis.
- Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.
- Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network.
- Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis.
- Effectiveness of semaglutide on survival outcomes in patients with type 2 diabetes and chronic kidney disease.
- Methodological concerns with the meta-analysis comparing insulin degludec/liraglutide and insulin glargine/lixisenatide.
- Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review.
- Exenatide for diagnosing endogenous hyperinsulinemic hypoglycemia: a randomized placebo-controlled, double-blind, cross-over proof-of-principle study.
- Exposure-adjusted safety and efficacy of GLP-I and GLP-1/GIP receptor agonists compared with non-GLP-I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects.
- The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults.
- Tirzepatide for Lipodystrophy.
- Integrating incretin-based therapy into type 2 diabetes management.
- Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?
- Once-Weekly Mazdutide in Obesity or Overweight. Reply.
- Ethical Considerations in the Use of Weight Loss Medications.
- A randomized controlled trial protocol of the cardiovascular safety and efficacy of liraglutide in the treatment of type 2 diabetes.
- Exenatide improves cisplatin induced ovarian damage through NLRP3, Nrf-2, and TLR4 pathways.
- Is pharmacotherapy enough for urgent weight loss in severely obese patients?
- Tirzepatide mitigates cognitive decline in zebrafish model of type 2 diabetes mellitus induced by high-fat diet.
- Exenatide substantially improves proinsulin conversion and cell survival that augment Ins2<sup>+/Akita</sup> beta cell function.
- Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1.
- Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson's disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study.
- [Effects of antidiabetic medications on metabolic-associated fatty liver disease].